Grant: Applied Research and Development Grants - Level 1

Regenerative medicine involving the transplantation of cell-based implants holds great promise for improving the clinical efficacy of conventional treatments. This is possible because the implantation of repair-specific cells (such as stem cells) have the ability to restore tissue to normal function. The current procedures to create cell-based products are all manual in nature and hence do not enable high reproducibility and cost-effectiveness. Automated production could potentially be achieved through the robotic duplication of manual actions; however, the general industry challenge is that existing robotic systems for basic cell culture are highly complex, require significant space for operation, and require a high capital equipment investment. Octane Biotechs challenge is to develop an innovative, cost-effective and automated bioreactor-based system to meet the clinical production challenges. The companys unique Automated Cell & Tissue Engineering System will integrate state-of-the-art bioreactors, biosensors and bioprocessing to enable routine production of cell-based products.